Busulfan 6mg Fresenius Injection
PDF Leaflet Revision Date: 28 July 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Conditioning treatment prior to haematopoietic progenitor cell transplantation.
Dosage (summary)
0.8 mg/kg IV infusion every 6 hours for 4 days (16 doses total).
Special Populations
- Hepatic impairment
- Obese patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding should be discontinued during treatment.
Key Drug Interactions
- Itraconazole
- Metronidazole
- Paracetamol
- Phenytoin
- Benzodiazepines
Contraindications
- Hypersensitivity to busulfan
- Pregnancy
- Hepatic insufficiency
Common side effects
- Neutropenia
- Thrombocytopenia
- Anaemia
- Seizures
- Nausea
Counselling Points
- Premedicate with anticonvulsants
- Monitor blood counts regularly
- Avoid pregnancy during and 6 months after treatment
Serious warnings
- Profound myelosuppression
- Risk of second malignancy
- Potential for hepatotoxicity
Important Disclaimer
The Busulfan 6mg Fresenius Injection professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
